Harith Rajagopalan Purchases 25,000 Shares of Fractyl Health (NASDAQ:GUTS) Stock

Fractyl Health, Inc. (NASDAQ:GUTS) CEO Harith Rajagopalan purchased 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The stock was acquired at an average cost of $0.73 per share, for a total transaction of $18,250.00. Following the transaction, the chief executive officer owned 540,557 shares in the company, valued at $394,606.61. This represents a 4.85% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Fractyl Health Price Performance

Shares of NASDAQ GUTS opened at $0.85 on Friday. Fractyl Health, Inc. has a fifty-two week low of $0.38 and a fifty-two week high of $2.45. The stock has a market cap of $134.85 million, a price-to-earnings ratio of -0.66 and a beta of 2.34. The company has a debt-to-equity ratio of 1.41, a quick ratio of 4.28 and a current ratio of 4.28. The firm’s 50-day simple moving average is $0.69 and its 200 day simple moving average is $1.07.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.23. As a group, research analysts anticipate that Fractyl Health, Inc. will post -0.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Fractyl Health

Several hedge funds have recently modified their holdings of GUTS. Woodline Partners LP lifted its position in shares of Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock worth $615,000 after buying an additional 165,786 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Fractyl Health during the 2nd quarter worth approximately $129,000. General Catalyst Group Management LLC bought a new position in shares of Fractyl Health during the 2nd quarter worth approximately $7,912,000. Jane Street Group LLC bought a new position in shares of Fractyl Health during the 2nd quarter worth approximately $31,000. Finally, Osaic Holdings Inc. lifted its position in shares of Fractyl Health by 460.3% during the 2nd quarter. Osaic Holdings Inc. now owns 59,645 shares of the company’s stock worth $97,000 after buying an additional 49,000 shares in the last quarter.

Analyst Ratings Changes

GUTS has been the topic of several recent analyst reports. Wall Street Zen raised shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Tuesday, May 12th. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, March 26th. Finally, HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.40.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.